ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.47
-0.31 (-4.57%)
Dec 5, 2025, 4:00 PM EST - Market closed
Company Description
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kristin Yarema |
Contact Details
Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States | |
| Phone | 858 345 6265 |
| Website | inmagenebio.com |
Stock Details
| Ticker Symbol | IMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G207 |
| ISIN Number | US45175G2075 |
| Employer ID | 81-1697316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristin Yarema Ph.D. | Chief Executive Officer, Director and Interim Principal Financial Officer |
| Erin Butler | Senior Vice President of Finance and Administration |
| Dr. Yufang Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Anna Vardanyan M.D., Ph.D. | Senior Vice President of Corporate and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2025 | 424B3 | Prospectus |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 424B3 | Prospectus |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 30, 2025 | 424B3 | Prospectus |